In memory of the industrial pharmacist and drug researcher Friedrich Stolz (see e.g. Pharmazeutische Zeitung 2010, 42 ) and his forward-looking innovative strength, the Division of Medicinal Chemistry of the German Chemical Society (GDCh) and the pharmaceutical/medicinal chemistry Division of the German Pharmaceutical Society (DPhG) have been awarding since 2022 the Friedrich-Stolz Award. The award is given to an individual or team from the industrial environment in even-numbered years and to one from academia in odd-numbered years. Recognition will be given for outstanding commitment, scientific discovery or innovative technology of proven relevance that contributes to substantial therapeutic innovation or sustainable development and goes beyond early stages of research. The award includes a certificate of award, prize money of 5,000 euros donated by the Divisions , a lecture at the "Frontiers in Medicinal Chemistry" Conference and two further lectures at one university and one industrial location within Germany.
A committee consisting of six people decides on the awarding of the prize: two board members of the GDCh Division (Chair/ Deputy Chair), two board members of the DPhG Division and two "external" people; If possible, one person per group comes from the university area and one from the industry area.
The price is currently not advertised.
The Friedrich-Stolz Award was awarded for the first time on March 16, 2022 on the occasion of the Online Conference "Frontiers in Medicinal Chemistry 2022" to Prof. Dr. Joachim Mittendorf, Dr. Markus Follmann and Dr. Michael Hahn (Bayer AG) in recognition of her work in discovering soluble guanylate cyclase (sGC) modulators.
"The award-winning work initially enabled the validation of sGC as a highly relevant cardiovascular target with early lead structures and the first clinical candidates. The active ingredients Riociguat and Vericiguat - both sGC stimulators - were developed based on the work of Prof. Dr. Joachim Mittendorf and Dr. Markus Follmanns successfully approved as a drug. Riociguat is now used to treat pulmonary arterial hypertension, Vericiguat for the treatment of chronic heart failure. Based on Dr. Michael Hahn's work, in addition to the sGC stimulators mentioned, sGC activators are now also in advanced clinical testing the runcaciguat as a treatment option for chronic kidney disease.The team's performance and innovative strength vividly demonstrate the key role of medicinal chemistry in the discovery of fundamental pharmacological principles and how medicinal chemistry works for the benefit of patients and can."
Award Committee 2022: Prof. Dr. Anna Hirsch (GDCh Division), Prof. Dr. Stefan Laufer (DPhG Division), Prof. Dr. Christa Müller (DPhG Division), Prof. Dr. Peter H. Seeberger (external; chair )
No participation due to bias : Dr. Ingo Hartung (external), Dr. Franz von Nussbaum (GDCh Division)
This page has been machine translated. If you have any feedback or comments please feel free to contact us.
last modified: 20.02.2023 17:29 H from Translator